The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3047-3052

  Yan, Yulan ^a   Liang, Hongjie ^a   Li, Taijie ^a   Li, Meng ^a   Li, Ruolin ^a   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Meta analysis; MMP; Polymorphism

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE;

ARTICLE; BLADDER CANCER; CANCER SUSCEPTIBILITY; DATA BASE; EMBASE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 84899124772     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1395-6     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-49.
3. Oosterlinck W. Chemotherapy: electromotive mitomycin in superficial bladder cancer. Nat Rev Clin Oncol. 2011;8:633-4.
4. Schmitz-Drager BJ. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur Urol. 2011;60:721-3.
5. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251-85.
6. Cassidy A, Wang W, Wu X, Lin J. Risk of urinary bladder cancer: a case-control analysis of industry and occupation. BMC Cancer. 2009;9:443.
7. Hirao Y, Kim WJ, Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol. 2009;19:494-9.
8. Taioli E, Raimondi S. Genetic susceptibility to bladder cancer. Lancet. 2005;366:610-2.
9. Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev. 2005;14:2569-78.
10. Li J, Luo F, Zhang H, Li L, Xu Y. The CCND1 G870A polymorphism and susceptibility to bladder cancer. Tumour Biol. 2013. doi: 10.1007/s13277-013- 1021-7.
11. Zhang C, Song X, Zhu M, Shi S, Li M, Jin L, et al. Association between MMP1-1607 1G>2G polymorphism and head and neck cancer risk: a meta-analysis. PLoS One. 2013;8:e56294.
12. Zhang H, Wen X, Lu X. Association between NAD(P)H:quinone oxidoreductase 1 rs1800566 polymorphism and risk of bladder cancer. Tumour Biol. 2013. doi: 10.1007/s13277-013-0909-6.
13. Wieczorek E, Reszka E, Jablonowski Z, Jablonska E, Beata Krol M, Grzegorczyk A, et al. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int. 2013. doi: 10.1111/bju.12230.
14. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007;13:2614-20.
15. Stetler-Stevenson WG, Liotta LA, Kleiner Jr DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-41.
16. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-4.
17. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001;11:143-52.
18. Aad G, Abbott B, Abdallah J, et al. Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the atlas detector at the LHC. Phys Rev Lett. 2010;105:161801.
19. Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers. 2010;29:37-46.
20. Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 2010;17:3068-75.
21. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006;66:11644-8.
22. Tasci AI, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int. 2008;101:503-7.
23. Zhong A, Yang W. MMP-2 and MMP-9 expression and clinical significance in bladder transitional cell carcinoma. Journal of Clinical Urology. 2005;22:461-4.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
27. Tobias A, Campbell MJ. Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health. 1999;53:583-4.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315:629-34.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
30. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973-8.
31. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729-34.
32. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71:7376-86.
33. Gong M, Yi Q, Wang W. Association between NQO1 C609T polymorphism and bladder cancer susceptibility: a systemic review and meta-analysis. Tumour Biol. 2013;34(5):2551-6.
34. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439-44.
35. Qin X, Peng Q, Qin A, Chen Z, Lin L, Deng Y, et al. Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. Diagn Pathol. 2012;7:136.
36. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97.
37. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.